NEOGEN (ANIMAL BIOSECURITY DIVISION) acquired by KERSIA

A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates.

Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe. The partnership will focus on product innovation (AI integration for planning) and potential strategic acquisitions to build a comprehensive HR platform for the healthcare sector.

Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care. This integration allows members to access benefits navigation, clinical guidance, and end‑to‑end care delivery through a single interface, with the explicit goal of improving utilization patterns, lowering total care costs, and enhancing member experience for employers and payers. The combined organization now serves over 20 million members and more than 1,700 employer and health‑plan clients, creating a large‑scale, digitally‑native health services platform with significant optionality for cross‑selling, technology integration, and further ecosystem expansion.

Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering. Under the new ownership structure, CEO Luca Borella retained his position and a significant minority stake. Ardian intends to leverage its global network and "Buy-and-Build" expertise to accelerate Masco's footprint in North America and Asia, while deepening its technological capabilities in the high-growth biologics and injectable drug sectors.

21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.

Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially. The primary goal was to provide Banook with the resources to accelerate its buy-and-build strategy, focusing on North American expansion and diversification into eCOA and biostatistics.

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.

Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets. The deal structure allowed the founder, Miroslav Reljanović, to roll over a portion of his equity and remain involved, ensuring continuity. Strategically, Permira aims to supercharge Ergomed's "Site Management" model and its pharmacovigilance capabilities through both organic investment and accretive M&A.

Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs).

Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization. The strategic rationale for Astorg is deeply rooted in acquiring a highly scalable platform investment within the rapidly professionalizing medical communications space. As the pharmaceutical industry shifts toward complex, next-generation therapeutics, the demand for specialized, high-science communication and rigorous data analytics has transformed medical affairs from a supportive function into a central commercial driver. Astorg intends to deploy its substantial dry powder and leverage its extensive healthcare expertise to accelerate the company's next phase of growth, supporting both organic initiatives and highly targeted, value-accretive strategic acquisitions.